EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes

Maja Witowska, Luigi Margiotta‐Casaluci, Periklis Pantazis, Margarita Dominguez‐Villar, Victoria Salem

Diabetic Medicine · 2026-11-05

DOI: 10.1111/dme.70495 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aims Type 1 diabetes (T1D) is a self‐driving autoimmune condition leading to the death of insulin‐producing β‐cells of the pancreas. β‐cell‐reactive immune cell extravasation into the intra‐islet space is fuelled by a cycle of inflammation including immune, vascular and endocrine dysfunction. Since clinical pancreatic biopsy is contraindicated, T1D research relies on static in vitro culture or in vivo models that either cannot fully replicate the dynamic interactions between the three different tissue types or differ greatly from the human disease process. Methods Recent advances in bioengineering have led to the emergence of Organ‐on‐Chip (OoC) platforms that aim to recapitulate the human diabetic pancreatic environment. Early T1D‐relevant OoC‐based research focused on the assessment of islet viability. This review turns its attention to the next frontier of vascularised and immune‐competent PoC models, which hold promise for the study of the insulitis of T1D and to predict treatment response to novel therapies. Results PoC models can incorporate technologies developed for cancer and non‐diabetes inflammation applications to inform chip design, vascularisation, immune perfusion and pancreatic component incorporation. An established PoC model can then be utilised for a detailed quantitative and qualitative analysis and functional correlation of the immune, vascular and pancreatic components according to an a priori Context of Use (CoU). Conclusion The ease of manufacturing, combined with a future possibility of a fully human autologous PoC, could enable high‐throughput screening of T1D tissue for underlying causes of patient heterogeneity that, in turn, could inform personalised treatment approaches, prolonged cell therapy survival and novel preventative measures.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →